{"id":"3c809f17-785f-536b-9437-c0e184bae8b2","stable_key":"cb568d28-484a-5c2e-9fcc-2d780358e514:c-lovit-mortality-component","predicate":"mortality_component_did_not_reach_statistical_significance","statement":"Day-28 mortality was 35.4% versus 31.6% (RR 1.17, 95% CI 0.98–1.40), while the combined primary endpoint was significant.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"c499c266-33e5-50f3-aa11-800e6961184e","mechanism_event_label":"The combined endpoint and mortality alone had different statistical results.","subject":{"id":"2047867f-9872-53b2-a553-71c911d0695b","slug":"ascorbic-acid","display_name":"L-Ascorbic acid","entity_type_key":"small_molecule"},"object":{"id":"8b4e65f7-cbc2-5065-88f5-5ef9f96d45db","slug":"sepsis-day28-mortality","display_name":"Sepsis mortality at day 28","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"c499c266-33e5-50f3-aa11-800e6961184e","stable_key":"cb568d28-484a-5c2e-9fcc-2d780358e514:c-lovit-mortality-component-event","event_type":"observed_intervention","label":"The combined endpoint and mortality alone had different statistical results.","description":"Day-28 mortality was 35.4% versus 31.6% (RR 1.17, 95% CI 0.98–1.40), while the combined primary endpoint was significant.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"2047867f-9872-53b2-a553-71c911d0695b","slug":"ascorbic-acid","display_name":"L-Ascorbic acid","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"8b4e65f7-cbc2-5065-88f5-5ef9f96d45db","slug":"sepsis-day28-mortality","display_name":"Sepsis mortality at day 28","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"experimental_model","value_text":"LOVIT: multicenter placebo-controlled randomized ICU trial; 872 randomized, 863 in primary analysis, with sepsis and vasopressor use.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"IV vitamin C 50 mg/kg every six hours for up to 96 hours versus matched placebo.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Confidence interval includes no difference; neither a proven mortality increase alone nor evidence of identical mortality.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Vitamin C research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"vitamin-c","display_name":"Vitamin C","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The combined endpoint and mortality alone had different statistical results.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[c-lamontagne2022] Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit (2022). https://pubmed.ncbi.nlm.nih.gov/35704292/ DOI: 10.1056/nejmoa2200644","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Human blood or whole-person endpoints","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"94291114-2583-500e-98ba-2a27b0a95f43","evidence_kind":"source_excerpt","locator":"Lines 1707-1717","start_line":1707,"end_line":1717,"excerpt":"### c-lovit-mortality-component\nDay-28 mortality was 35.4% versus 31.6% (RR 1.17, 95% CI 0.98–1.40), while the combined primary endpoint was significant.\nCondition category: normal\nnutrient_topic: Vitamin C research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The combined endpoint and mortality alone had different statistical results.\norganism: Homo sapiens\ntissue_or_cell_type: Human blood or whole-person endpoints\nexperimental_model: LOVIT: multicenter placebo-controlled randomized ICU trial; 872 randomized, 863 in primary analysis, with sepsis and vasopressor use.\nlimitations: Confidence interval includes no difference; neither a proven mortality increase alone nor evidence of identical mortality.\nexposure: IV vitamin C 50 mg/kg every six hours for up to 96 hours versus matched placebo.\n[c-lamontagne2022] Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit (2022). https://pubmed.ncbi.nlm.nih.gov/35704292/ DOI: 10.1056/nejmoa2200644","model_system":"LOVIT: multicenter placebo-controlled randomized ICU trial; 872 randomized, 863 in primary analysis, with sepsis and vasopressor use.","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [c-lamontagne2022] Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit (2022). https://pubmed.ncbi.nlm.nih.gov/35704292/ DOI: 10.1056/nejmoa2200644","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"fa811221-13bd-5c10-adc1-eaf097c7703c","stable_key":"import-cb568d28-484a-5c2e-9fcc-2d780358e514","title":"Vitamin C: mechanisms, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"b7fd83f956abb81855f2ea23199ba14e465cd91f4a2ac560277ec21ddafd7bfc","revision_id":"6cde9bbb-d712-5746-82a6-85b144253efa","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}